Incannex Healthcare Past Earnings Performance
Past criteria checks 0/6
Incannex Healthcare's earnings have been declining at an average annual rate of -43.7%, while the Pharmaceuticals industry saw earnings growing at 31.2% annually. Revenues have been growing at an average rate of 5.7% per year.
Key information
-43.7%
Earnings growth rate
-13.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 5.7% |
| Return on equity | -23.7% |
| Net Margin | -1,970.6% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Incannex Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 1 | -20 | 9 | 9 |
| 31 Mar 23 | 1 | -19 | 9 | 8 |
| 31 Dec 22 | 1 | -18 | 9 | 7 |
| 30 Sep 22 | 1 | -17 | 8 | 6 |
| 30 Jun 22 | 1 | -15 | 7 | 5 |
| 31 Mar 22 | 1 | -14 | 6 | 5 |
| 31 Dec 21 | 1 | -13 | 6 | 5 |
| 30 Sep 21 | 1 | -12 | 6 | 5 |
| 30 Jun 21 | 2 | -11 | 6 | 5 |
| 31 Dec 20 | 2 | -6 | 3 | 4 |
| 30 Sep 20 | 1 | -5 | 2 | 3 |
| 30 Jun 20 | 1 | -4 | 2 | 2 |
| 31 Dec 19 | 0 | -2 | 1 | 1 |
| 30 Sep 19 | 0 | -2 | 1 | 1 |
| 30 Jun 19 | 0 | -1 | 1 | 1 |
| 31 Mar 19 | 1 | -3 | 3 | 0 |
| 31 Dec 18 | 1 | -3 | 4 | 0 |
| 30 Sep 18 | 1 | -3 | 3 | 0 |
| 30 Jun 18 | 1 | -3 | 3 | 0 |
| 31 Mar 18 | 1 | -3 | 3 | 0 |
| 31 Dec 17 | 1 | -3 | 3 | 0 |
| 30 Sep 17 | 0 | -12 | 3 | 0 |
| 30 Jun 17 | 0 | -21 | 2 | 0 |
| 31 Mar 17 | 0 | -20 | 2 | 0 |
| 31 Dec 16 | 0 | -19 | 2 | 0 |
| 30 Sep 16 | 0 | -10 | 1 | 0 |
| 30 Jun 16 | 0 | -1 | 1 | 0 |
Quality Earnings: IHL is currently unprofitable.
Growing Profit Margin: IHL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IHL is unprofitable, and losses have increased over the past 5 years at a rate of 43.7% per year.
Accelerating Growth: Unable to compare IHL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IHL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10%).
Return on Equity
High ROE: IHL has a negative Return on Equity (-23.75%), as it is currently unprofitable.